Recently, clinical data are promising for chronic heart failure patients with reduced ejection fraction as they are superior to angiotensin-converting enzyme (ACE) inhibition by reducing risk of death and hospitalization in heart failure [176]. This evidence concerns the gene ACE and heart failure.